Article | June 1, 2020

Lipid-Based Formulations For Early-Stage Clinical Trials

Source: Lonza Pharma & Biotech

By Annabel Igonin, Senior Manager Pharmaceutical Formulation Development, Product Development, Lonza Ploermel, France and Jenifer Mains, Senior Manager Pharmaceutical Formulation Development, Product Development, Lonza Edinburgh, UK

Capsule 450x300

A large majority (80% or more) of drug candidates currently under development are poorly water-soluble and experience bioavailability challenges, leading to difficulties in drug product formulation.  Drug developers today also face accelerated development timelines, often due to specialized medicines and regulatory pathways such as orphan drugs, break-through and fast-track designations and NDA 505(b)2 programs. Both of these challenges are especially pressing for small or emerging pharma and biotech companies, which tend to lack resources in-house for bioavailability enhancement or rapid drug development.

Several technologies, including particle size reduction and nano-milling, salt formation, amorphous solid dispersions and lipid-based drug delivery systems, have extensive track records in enhancing oral bioavailability. These technologies can also be used in the context of accelerated drug development. But not all technologies are appropriate for all molecules, and developers can benefit from avoiding spending time and API testing different technologies.

The choice between enabling technologies depends on physicochemical and biologic parameters, as well as the target product profile of the candidate drug. One effective approach to technology selection relies on using in silico and in vitro formulation and testing methodologies that are highly correlated to in vivo performance. Such R&D-derived capabilities may help drug developers quickly and accurately select the most effective bioavailability-enhancing technologies for candidate molecules, avoiding a lengthier trial-and-error approach. For certain molecules, the most appropriate technology for bioavailability enhancement and accelerated development will be lipid-based formulations (LBF), supported by in silico development tools.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Drug Discovery Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: